Skip to main
ALLO
ALLO logo

ALLO Stock Forecast & Price Target

ALLO Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 44%
Buy 56%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allogene Therapeutics has demonstrated a commitment to enhancing patient safety and simplifying clinical procedures through its strategic shift to standard FC lymphodepletion in the ALPHA3 trial, which preserves the trial's statistical integrity. The company's pipeline reflects a strong focus on off-the-shelf T-cell therapies intended for diverse cancer profiles, indicating robust scalability and potential for broad patient eligibility. Additionally, the significant participation in minimal residual disease (MRD) screening, with over 90% patient consent rates, underscores the strong engagement in the enrollment process, supporting Allogene's trajectory towards successful clinical outcomes and commercial viability.

Bears say

Allogene Therapeutics Inc faces substantial risks regarding the approval of its clinical assets, with potential delays likely to adversely affect its stock performance. The inherent uncertainties associated with clinical trials may lead to failures in demonstrating adequate efficacy or safety, which could further jeopardize the company’s prospects. Additionally, the regulatory landscape introduces further commercial risks that could impede the progression and financial viability of Allogene's therapeutic offerings.

ALLO has been analyzed by 9 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 56% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allogene Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allogene Therapeutics Inc (ALLO) Forecast

Analysts have given ALLO a Buy based on their latest research and market trends.

According to 9 analysts, ALLO has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allogene Therapeutics Inc (ALLO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.